Biostem Technologies Stock Performance
| BSEM Stock | USD 14.44 0.98 6.36% |
On a scale of 0 to 100, Biostem Technologies holds a performance score of 8. The firm shows a Beta (market volatility) of -0.65, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Biostem Technologies are expected to decrease at a much lower rate. During the bear market, Biostem Technologies is likely to outperform the market. Please check Biostem Technologies' sortino ratio, skewness, price action indicator, as well as the relationship between the potential upside and rate of daily change , to make a quick decision on whether Biostem Technologies' price patterns will revert.
Risk-Adjusted Performance
8 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Biostem Technologies are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. In spite of very uncertain technical and fundamental indicators, Biostem Technologies displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 140.7 K | |
| Free Cash Flow | -581.6 K |
Biostem |
Biostem Technologies Relative Risk vs. Return Landscape
If you would invest 1,016 in Biostem Technologies on September 24, 2024 and sell it today you would earn a total of 428.00 from holding Biostem Technologies or generate 42.13% return on investment over 90 days. Biostem Technologies is currently generating 0.8276% in daily expected returns and assumes 7.3874% risk (volatility on return distribution) over the 90 days horizon. In different words, 65% of otc stocks are less volatile than Biostem, and 84% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Biostem Technologies Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Biostem Technologies' investment risk. Standard deviation is the most common way to measure market volatility of otc stocks, such as Biostem Technologies, and traders can use it to determine the average amount a Biostem Technologies' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.112
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | BSEM | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 7.39 actual daily | 65 65% of assets are less volatile |
Expected Return
| 0.83 actual daily | 16 84% of assets have higher returns |
Risk-Adjusted Return
| 0.11 actual daily | 8 92% of assets perform better |
Based on monthly moving average Biostem Technologies is performing at about 8% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Biostem Technologies by adding it to a well-diversified portfolio.
Biostem Technologies Fundamentals Growth
Biostem OTC Stock prices reflect investors' perceptions of the future prospects and financial health of Biostem Technologies, and Biostem Technologies fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Biostem OTC Stock performance.
| Return On Equity | -2.21 | |||
| Return On Asset | -0.6 | |||
| Operating Margin | (18.22) % | |||
| Current Valuation | 37.89 M | |||
| Shares Outstanding | 9.24 M | |||
| Price To Earning | (0.49) X | |||
| Price To Sales | 151.81 X | |||
| Revenue | 2.52 M | |||
| EBITDA | (1.59 M) | |||
| Cash And Equivalents | 1.37 M | |||
| Cash Per Share | 0.12 X | |||
| Total Debt | 1.32 M | |||
| Book Value Per Share | (0.26) X | |||
| Cash Flow From Operations | (581.57 K) | |||
| Earnings Per Share | (0.58) X | |||
| Total Asset | 2.67 M | |||
| Retained Earnings | (5.31 M) | |||
| Current Asset | 307 K | |||
| Current Liabilities | 1.86 M | |||
About Biostem Technologies Performance
By examining Biostem Technologies' fundamental ratios, stakeholders can obtain critical insights into Biostem Technologies' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Biostem Technologies is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
BioStem Technologies, Inc., a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. BioStem Technologies, Inc. was incorporated in 2006 and is based in Pompano Beach, Florida. Biostem Technologies is traded on OTC Exchange in the United States.Things to note about Biostem Technologies performance evaluation
Checking the ongoing alerts about Biostem Technologies for important developments is a great way to find new opportunities for your next move. OTC Stock alerts and notifications screener for Biostem Technologies help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Biostem Technologies is way too risky over 90 days horizon | |
| Biostem Technologies appears to be risky and price may revert if volatility continues | |
| Biostem Technologies currently holds 1.32 M in liabilities. Biostem Technologies has a current ratio of 0.25, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Biostem Technologies until it has trouble settling it off, either with new capital or with free cash flow. So, Biostem Technologies' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Biostem Technologies sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Biostem to invest in growth at high rates of return. When we think about Biostem Technologies' use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 2.52 M. Net Loss for the year was (2.39 M) with profit before overhead, payroll, taxes, and interest of 163.78 K. | |
| Biostem Technologies currently holds about 1.37 M in cash with (581.57 K) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.12. | |
| Latest headline from MacroaxisInsider: Acquisition by Seidel-dugan Cynthia of 79516 shares of Werewolf Therapeutics at 11.55 subject to Rule 16b-3 |
- Analyzing Biostem Technologies' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Biostem Technologies' stock is overvalued or undervalued compared to its peers.
- Examining Biostem Technologies' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Biostem Technologies' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Biostem Technologies' management team can help you assess the OTC Stock's leadership.
- Pay attention to analyst opinions and ratings of Biostem Technologies' otc stock. These opinions can provide insight into Biostem Technologies' potential for growth and whether the stock is currently undervalued or overvalued.
Other Information on Investing in Biostem OTC Stock
Biostem Technologies financial ratios help investors to determine whether Biostem OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Biostem with respect to the benefits of owning Biostem Technologies security.